New Prague, Minnesota--(Newsfile Corp. - October 13, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a leader in innovative airway clearance technologies, today announced that Company management will participate in the LD Micro Main Event XIX Conference being held October 19-21, 2025 in San Diego. Electromed President and Chief Executive Officer Jim Cunniff will present on Monday, October 20 at 10:00 am PT. Interested parties may access a live webcast of the presentation using the following link Electromed LD Micro Main Event XIX Webcast. The link will also be posted on the Electromed Investor Relations website under Events & Presentations.
Institutional investors may register for the event and request one-on-one meetings through their LD Micro representative.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Brad Nagel, Chief Financial Officer
(952) 758-9299
This email address is being protected from spambots. You need JavaScript enabled to view it.
Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$25.27 |
| Daily Change: | -1.08 -4.10 |
| Daily Volume: | 58,642 |
| Market Cap: | US$211.760M |
November 12, 2025 August 26, 2025 April 03, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load